UNSPSC 51111643: Ketotrexate

This classification denotes a folate antagonist with the molecular formula C21H27N7O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 504RN634MM, chemically known as n-(p-((2-(2-amino-1,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6-pteridinyl)ethyl)amino)benzoyl)-l-glutamic acid but generally known as ketotrexate, which bears US NIH Compound Identifier 68691. European Medicines Agency schedules Ketotrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08378MIG.

UNSPSC 51111643 Ketotrexate is a Commodity code representing a specific pharmaceutical product. State and local governments procure ketotrexate through pharmacy benefit programs and health plan contracting mechanisms, typically as part of broader pharmaceutical supply agreements rather than as standalone product purchases. The Texas Health and Human Services Commission's recent Request for Information on a Direct-to-Manufacturer Prescriptions program demonstrates that state health agencies are exploring alternative sourcing and contracting models beyond traditional pharmacy benefit manager and wholesale distribution channels, seeking vendors capable of negotiating direct contracts with self-insured employers and government health plans using net pricing models and value-based arrangements. State health and human services agencies represent the primary issuing bodies under this code, procuring pharmaceuticals as components of Medicaid, employee health plans, and specialty pharmacy programs.

The most recent activity appears concentrated in Texas, where the HHS Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct pharmaceutical contracting. The RFI represents an exploratory phase designed to inform future procurement strategy rather than a binding competitive solicitation, with no award value, set-asides, or formal response timeline specified. The state indicated that formal RFP solicitations with established financial and temporal parameters would likely follow this information-gathering phase, suggesting that competitive opportunities for ketotrexate sourcing may emerge from this initiative. Limited recent public activity under this Commodity code suggests either concentrated procurement through standing contracts or relatively low transaction volume in public notices.